FOXA vs LYEL · P/E 14, rev $17.13B vs rev $6.0K
Fox Corp Class A (FOXA) versus Lyell Immunopharma Inc (LYEL) — a side-by-side from cached financials, not a winner call.
Fox Corp Class A (FOXA) is a entertainment company listed on US.
Lyell Immunopharma Inc (LYEL) is a biotechnology company listed on US.
Latest reported FOXA revenue for 2026-06-30 was $17.13B. Net income was $1.73B. Revenue was up 5.1% from 2025-06-30 to 2026-06-30. FOXA currently screens at market cap $24.50B and trailing P/E 14.1.
Latest reported LYEL revenue for 2026-06-30 was $6.0K. Net income was -$68.9M. LYEL currently screens at market cap $143.5M.
FOXA currently screens at market cap $24.50B and trailing P/E 14.1. LYEL currently screens at market cap $143.5M.
Not investment advice. Open the FOXA and LYEL stock pages for the full models.
Not investment advice.